Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday

Xilio Therapeutics (NASDAQ:XLO) is projected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.72 million for the quarter, compared to analysts’ expectations of $2.26 million. On average, analysts expect Xilio Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Price Performance

Shares of NASDAQ XLO opened at $0.75 on Monday. Xilio Therapeutics has a one year low of $0.63 and a one year high of $1.70. The business’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $0.93. The company has a market capitalization of $38.62 million, a P/E ratio of -0.43 and a beta of -0.38.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.